Wang Alexander S, Agharazi Hanieh, Parmar Aetan, Kilbane Camilla W, Cameron Lauren, Shaikh Aasef G, Gunzler Steven A
Movement Disorders Center, Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.
Department of Neurology, Case Western Reserve University, Cleveland, OH, United States.
Dystonia. 2025 Jul 9;4. doi: 10.3389/dyst.2025.14652.
Pain is a common symptom of cervical dystonia (CD). The mainstay of treatment of CD is botulinum toxin, which is known to have benefits in relieving pain. We aimed to characterize the locations of pain in patients with CD, and to assess what factors may predict pain reduction following botulinum toxin injection.
We conducted a single-center observational study of CD patients who reported pain and who received botulinum toxin treatment. On the day of their toxin injection (in the untreated state), they filled out a survey evaluating primary and secondary sites of pain as indicated on a diagram, as well as Pain Numeric Rating Scale assessing average pain over the past 24 h. Two weeks later, they filled out a follow-up survey (in the treated state) to evaluate whether location and pain intensity changed.
55 people with CD participated in the study, and 40 of them completed both surveys. Most patients reported pain localization over the posterior musculature, especially in the areas overlying superior trapezius and levator scapulae. 21 of 40 (52.5%) patients reported improvement of pain intensity by ≥ 30% in the primary site of pain. The mean improvement in pain intensity was 30.4% (SD = 32.4%), with a mean improvement on Numeric Rating Scale of 2.13 (SD = 2.02). 68% of patients received injections into or close to their primary site of pain. Using univariate linear regression, there was no clear effect of age, sex, muscles injected, or TWSTRS motor subscale on the degree of pain improvement. The locations of pain remained relatively stable in the post-treatment state.
We confirmed that botulinum toxin is effective for treatment of pain related to CD. We also gained insight into the typical locations of pain in CD by generating a heat map, showing pain most often in the regions of upper trapezius, levator scapulae, and splenius cervicus and capitis. Although there was not a significant correlation between the site of botulinum toxin injection and pain improvement, larger studies are needed to better determine optimal treatment strategies.
疼痛是颈部肌张力障碍(CD)的常见症状。CD治疗的主要方法是肉毒杆菌毒素,已知其在缓解疼痛方面有效果。我们旨在明确CD患者疼痛的部位,并评估哪些因素可能预测肉毒杆菌毒素注射后疼痛减轻。
我们对报告有疼痛且接受肉毒杆菌毒素治疗的CD患者进行了一项单中心观察性研究。在毒素注射当天(未治疗状态),他们填写了一份调查问卷,评估图表所示的主要和次要疼痛部位,以及评估过去24小时平均疼痛程度的疼痛数字评分量表。两周后,他们填写了一份随访调查问卷(治疗状态),以评估疼痛部位和强度是否发生变化。
55名CD患者参与了研究,其中40人完成了两份调查问卷。大多数患者报告疼痛定位于后部肌肉组织,尤其是斜方肌上部和肩胛提肌上方区域。40名患者中有21名(52.5%)报告主要疼痛部位的疼痛强度改善≥30%。疼痛强度的平均改善率为30.4%(标准差=32.4%),数字评分量表的平均改善值为2.13(标准差=2.02)。68%的患者在主要疼痛部位或其附近接受了注射。使用单变量线性回归分析,年龄、性别、注射肌肉或TWSTRS运动亚量表对疼痛改善程度没有明显影响。治疗后疼痛部位相对稳定。
我们证实肉毒杆菌毒素对治疗与CD相关的疼痛有效。我们还通过生成热图深入了解了CD中疼痛的典型部位,显示疼痛最常出现在斜方肌上部、肩胛提肌以及颈夹肌和头夹肌区域。虽然肉毒杆菌毒素注射部位与疼痛改善之间没有显著相关性,但需要更大规模的研究来更好地确定最佳治疗策略。